Reviewer's report

Title: Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.

Version: 2 Date: 31 May 2012

Reviewer: Sonal Gandhi

Reviewer's report:

Discretionary Revisions

1. add that use in provinces with reimbursement mechanisms likely increasing and field evaluations in these centres would be helpful to establish impact on practice; a few of these are ongoing in Ontario.

2. mention more explicitly that newer third generation anthracycline-taxane regimens have different costs and slightly better efficacy so analysis with such data would be more applicable to current practice landscape.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I declare that I have no competing interests.